Adaptive Biotechnologies Corp. is trading 9.5% down at $15.81 in after-hours trading after announcing a proposed offering of $250 million in convertible senior notes due 2031.
-
The company also revealed plans to pursue a separation of its Minimal Residual Disease (MRD) and Immune Medicine businesses, evaluating strategic alternatives for Immune Medicine.
-
These significant company-specific developments likely serve as catalysts for today's price decline.